JP2012508215A - 有機化合物 - Google Patents

有機化合物 Download PDF

Info

Publication number
JP2012508215A
JP2012508215A JP2011535129A JP2011535129A JP2012508215A JP 2012508215 A JP2012508215 A JP 2012508215A JP 2011535129 A JP2011535129 A JP 2011535129A JP 2011535129 A JP2011535129 A JP 2011535129A JP 2012508215 A JP2012508215 A JP 2012508215A
Authority
JP
Japan
Prior art keywords
salt
ray powder
salt according
peaks
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011535129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508215A5 (enExample
Inventor
ムッツ，ミハエル
ヨルディン，グイード
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42062355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2012508215(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2012508215A publication Critical patent/JP2012508215A/ja
Publication of JP2012508215A5 publication Critical patent/JP2012508215A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/122—Propionic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2011535129A 2008-11-11 2009-11-10 有機化合物 Withdrawn JP2012508215A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08168862.4 2008-11-11
EP08168862 2008-11-11
PCT/EP2009/064889 WO2010055027A2 (en) 2008-11-11 2009-11-10 Organic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015089480A Division JP2015178503A (ja) 2008-11-11 2015-04-24 有機化合物

Publications (2)

Publication Number Publication Date
JP2012508215A true JP2012508215A (ja) 2012-04-05
JP2012508215A5 JP2012508215A5 (enExample) 2012-12-20

Family

ID=42062355

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011535129A Withdrawn JP2012508215A (ja) 2008-11-11 2009-11-10 有機化合物
JP2015089480A Withdrawn JP2015178503A (ja) 2008-11-11 2015-04-24 有機化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015089480A Withdrawn JP2015178503A (ja) 2008-11-11 2015-04-24 有機化合物

Country Status (20)

Country Link
US (2) US8680146B2 (enExample)
EP (1) EP2358660A2 (enExample)
JP (2) JP2012508215A (enExample)
KR (1) KR20110086142A (enExample)
CN (2) CN105198760A (enExample)
AU (1) AU2009315735B2 (enExample)
BR (1) BRPI0921533A2 (enExample)
CA (1) CA2741974A1 (enExample)
CL (1) CL2011001041A1 (enExample)
CO (1) CO6382154A2 (enExample)
EC (1) ECSP11011121A (enExample)
IL (1) IL212073A0 (enExample)
MA (1) MA32877B1 (enExample)
MX (1) MX2011004924A (enExample)
NZ (1) NZ591999A (enExample)
PE (1) PE20120012A1 (enExample)
RU (1) RU2543621C2 (enExample)
TN (1) TN2011000187A1 (enExample)
WO (1) WO2010055027A2 (enExample)
ZA (1) ZA201102272B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502168A (ja) * 2015-01-20 2018-01-25 ハンダ ファーマシューティカルズ エルエルシー 安定な固体フィンゴリモド剤形
JP2024521882A (ja) * 2021-05-31 2024-06-04 上海雲晟研新生物科技有限公司 フィンゴリモド薬用塩、製造方法、それを含む医薬組成物及び使用

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973025B2 (en) 2005-05-26 2011-07-05 Neuron Systems, Inc. Compositions and methods of treating retinal disease
CN105198760A (zh) * 2008-11-11 2015-12-30 诺华股份有限公司 芬戈莫德的盐
US8766005B2 (en) 2009-07-24 2014-07-01 Ratiopharm Gmbh Process for producing fingolimod salts
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
BR112013010075A2 (pt) 2010-10-28 2017-10-24 Mapi Pharma Ltd compostos intermediários e processo para a preparação de fingolimod
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
EP2505589A1 (en) 2011-04-01 2012-10-03 Johann Wolfgang Goethe-Universität Frankfurt am Main Novel sphingolipid heterocyclic compounds as modulators of sphingolipid signaling and uses thereof
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
EP2964210B1 (en) 2013-03-05 2023-10-04 Biocon Limited A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
WO2015053879A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
EP3054933A4 (en) 2013-10-11 2017-03-15 Teikoku Pharma USA, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CA2996183A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
EP3466934B1 (en) 2016-05-31 2024-03-27 Taiho Pharmaceutical Co., Ltd. Sulfonamide compounds or salt thereof as ribonucleotide reductase inhibitors for treating cancer
RU2627691C1 (ru) * 2016-07-06 2017-08-10 Олег Ростиславович Михайлов Кристаллическая η-модификация 2-амино-2-(2-(4-октилфенил)этил)пропан-1,3-диол гидрохлорида, способ её получения и фармацевтическая композиция на её основе
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
AU2018377036B2 (en) 2017-11-29 2022-04-14 Taiho Pharmaceutical Co., Ltd. Sulfonamide compounds and use thereof
US20210261528A1 (en) * 2018-06-29 2021-08-26 Forma Therapeutics, Inc. Salts of (s)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)(cyclopropyl)methanone and solid forms thereof
CN112714762A (zh) * 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途
WO2020223685A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2020223717A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
KR20220093330A (ko) 2019-10-31 2022-07-05 이도르시아 파마슈티컬스 리미티드 Cxcr7 안타고니스트와 s1p1 수용체 조절인자의 조합
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001072585A (ja) * 1999-06-30 2001-03-21 Akira Matsumori ウイルス性心筋炎の予防または治療薬剤
JP2004534788A (ja) * 2001-06-08 2004-11-18 ノバルティス アクチエンゲゼルシャフト インスリン産生細胞移植片拒絶の処置または予防
JP2005535679A (ja) * 2002-07-24 2005-11-24 ノバルティス アクチエンゲゼルシャフト 心臓疾患におけるｓ１ｐレセプターアゴニストの使用
WO2007143081A2 (en) * 2006-06-02 2007-12-13 The Ohio State University Research Foundation Therapeutic agents for the treatment of lymphoid malignancies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE172711T1 (de) 1992-10-21 1998-11-15 Yoshitomi Pharmaceutical 2-amino-1, 3- propandiolverbindung und immunosuppressium
ECSP951461A (es) 1995-06-07 1998-04-07 SINTESIS DE 3- {4-(2- AMINOETOXI) BENZOIL]-2-ARIL-6- HIDROXIBENZO {b] TIOFENOS (CASO X- 9295B)
ECSP972265A (es) 1997-09-23 1998-11-30 Dihidrato de d-olanzapina
FR2785607B1 (fr) 1998-11-09 2001-02-09 Rhodia Chimie Sa Procede de preparation de tris(ether-amine)
WO2000027798A1 (en) * 1998-11-11 2000-05-18 Novartis Ag Production of 2-amino-2-[2-(4-c2-20-alkyl-phenyl)ethyl]propane-1,3-diols
BR0311173A (pt) * 2002-05-16 2005-03-15 Novartis Ag Uso de agentes de ligação do receptor de edg em câncer
CN101797241B (zh) 2003-04-08 2013-03-27 诺瓦提斯公司 包含s1p受体激动剂和糖醇的固体药物组合物
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
JP2009510112A (ja) * 2005-09-30 2009-03-12 ノバルティス アクチエンゲゼルシャフト 有機化合物の組合せ剤
WO2009100116A1 (en) * 2008-02-04 2009-08-13 Medical College Of Georgia Research Institute Oligodendrocyte precursor cell composition and methods of use
CN105198760A (zh) * 2008-11-11 2015-12-30 诺华股份有限公司 芬戈莫德的盐

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001072585A (ja) * 1999-06-30 2001-03-21 Akira Matsumori ウイルス性心筋炎の予防または治療薬剤
JP2004534788A (ja) * 2001-06-08 2004-11-18 ノバルティス アクチエンゲゼルシャフト インスリン産生細胞移植片拒絶の処置または予防
JP2005535679A (ja) * 2002-07-24 2005-11-24 ノバルティス アクチエンゲゼルシャフト 心臓疾患におけるｓ１ｐレセプターアゴニストの使用
WO2007143081A2 (en) * 2006-06-02 2007-12-13 The Ohio State University Research Foundation Therapeutic agents for the treatment of lymphoid malignancies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
塩路雄作著, 固形製剤の製造技術, vol. 普及版, JPN6011023134, 27 January 2003 (2003-01-27), pages 9 - 12, ISSN: 0002971842 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502168A (ja) * 2015-01-20 2018-01-25 ハンダ ファーマシューティカルズ エルエルシー 安定な固体フィンゴリモド剤形
JP2024521882A (ja) * 2021-05-31 2024-06-04 上海雲晟研新生物科技有限公司 フィンゴリモド薬用塩、製造方法、それを含む医薬組成物及び使用

Also Published As

Publication number Publication date
NZ591999A (en) 2013-06-28
AU2009315735A1 (en) 2010-05-20
ZA201102272B (en) 2011-12-28
TN2011000187A1 (en) 2012-12-17
ECSP11011121A (es) 2011-07-29
MA32877B1 (fr) 2011-12-01
RU2543621C2 (ru) 2015-03-10
AU2009315735B2 (en) 2013-01-10
KR20110086142A (ko) 2011-07-27
BRPI0921533A2 (pt) 2016-01-12
CN105198760A (zh) 2015-12-30
EP2358660A2 (en) 2011-08-24
RU2011123365A (ru) 2012-12-20
US20140235722A1 (en) 2014-08-21
CL2011001041A1 (es) 2011-10-07
US20110218248A1 (en) 2011-09-08
CO6382154A2 (es) 2012-02-15
MX2011004924A (es) 2011-05-30
JP2015178503A (ja) 2015-10-08
WO2010055027A2 (en) 2010-05-20
PE20120012A1 (es) 2012-02-02
US8680146B2 (en) 2014-03-25
IL212073A0 (en) 2011-06-30
CN102256933A (zh) 2011-11-23
CA2741974A1 (en) 2010-05-20
WO2010055027A3 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
JP2012508215A (ja) 有機化合物
KR101393994B1 (ko) 핑골리모드 ｈｃｌ의 결정질 형태
US9682988B2 (en) Solid salt form of α-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
AU2013100530A4 (en) Crystalline forms of fingolimod HCL
AU2013203470A1 (en) Salts of fingolimod

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140603

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140909

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150424

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150616

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150710

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20160815